Related Experiment Video

Updated: Jan 23, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K

Research Progress of Axl Inhibitors

Zhi-Gang Sun1,2, Jian-Hua Liu1, Jin-Mai Zhang3

  • 1Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi 276400, China.

Current Topics in Medicinal Chemistry
|June 21, 2019
PubMed

Insights

Axl receptor tyrosine kinase (RTK) inhibitors show promise for overcoming chemotherapy resistance and treating cancers like breast and lung cancer. Research into these inhibitors is advancing rapidly.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Axl, a TAM family receptor tyrosine kinase (RTK), is activated by Growth arrest-specific 6 (Gas6).
  • Axl is expressed in various tissues, including macrophages and endothelial cells.
  • Overexpression and activation of Axl correlate with enhanced chemotherapy resistance, proliferation, invasion, and metastasis in numerous human cancers.

Purpose of the Study:

  • To review recent research progress on Axl inhibitors.
  • To highlight the significance of Axl inhibitors in cancer treatment, particularly for drug-resistant cancers.

Main Methods:

  • Literature review of recent studies on Axl inhibitors.
  • Analysis of Axl's role in cancer signaling pathways and drug resistance.

Main Results:

  • Axl's involvement in key cancer-promoting pathways has been elucidated.
  • Various Axl inhibitors are under active investigation and development.
  • Axl inhibitors represent a promising strategy to overcome therapeutic resistance.

Conclusions:

  • Targeting Axl offers a potential therapeutic avenue for various human cancers.
  • Developing effective Axl inhibitors is crucial for improving cancer treatment outcomes and addressing drug resistance.
  • Continued research into Axl inhibitors is warranted.
Keywords:
AxlCancerDrug resistanceGilteritinibNatural productsTargeted therapy.

More Related Videos

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

27.5K
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

15.1K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
616
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.4K